Bioequivalency Study of Oxcarbazepine 600 mg Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The objective of this study was to assess bioequivalence of a potential generic 600 mb
oxcarbazepine tablet formulation compared with Novartis Pharmaceutical's 600 mg oxcarbazepine
tablet, Trileptal, following a single 600 mg dose, administered with food.